The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2294-2302

  Thomas, Eva ^a   Holmes, Frankie A ^a   Smith, Terry L ^a   Buzdar, Aman U ^a   Frye, Debra K ^a   Fraschini, Giuseppe ^a   Singletary, S Eva ^a   Theriault, Richard L ^a   McNeese, Marsha D ^a   Ames, Frederick ^a   Walters, Ronald ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINATE CALCIUM; METHOTREXATE; PREDNISONE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASTECTOMY; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; BREAST TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL RATE;

EID: 2942702177     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.207     Document Type: Article

References (23)

1. Jemal A, Tiwari R, Murray T, et al: Cancer statistics 2004. CA Cancer J Clin 54:8-29, 2004
2. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
3. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from NSABP B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
4. Feldman L, Hortobagyi G, Buzdar A, et al: Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578-2581, 1986
5. McCready D, Hortobagyi G, Kau S, et al: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124: 21-25, 1989
6. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
7. Kuerer H, Newman L, Buzdar A, et al: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176:502-509, 1998
8. Kuerer H, Sahin A, Hunt K: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230:72-78, 1999
9. Kuerer H, Newman L, Smith T, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
10. Pierga J, Mouret E, Dieras V, et al: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83:1480-1487, 2000
11. American Joint Committee on Cancer: Beahrs OH, Myers MH (eds): Manual for Staging of Cancer (ed 4). Philadelphia, PA, JB Lippincott, 1983, pp 127-133
12. Smith I, Heys S, Hutcheon A, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
13. Helvie M, Joynt L, Cody R, et al: Locally advanced breast carcinoma: Accuracy of mammography vs clinical examination in the prediction of residual disease after chemotherapy. Radiology 198:327-332, 1996
14. Herrada J, Iyer R, Atkinson E, et al: Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast cancer. Clin Cancer Res 3:1565-1569, 1997
15. Huber S, Wagner M, Zuna I, et al: Locally advanced breast carcinoma: Evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res 20:553-558, 2000
16. Buzdar A, Singletary S, Theriault R, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:12-17, 1999
17. Henderson I, Berry D, Demetri G, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 21:976-983, 2003
18. Buzdar A, Singletary S, Valero V, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002
19. Mamounas E, Bryant J, Lembersky B, et al: Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 22:4, 2003 (abstr 12)
20. Bear H, Andersen S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 21: 4165-4174, 2003
21. Green M, Buzdar A, Smith T, et al: Weekly paclitaxel followed by FAC in the neoadjuvant setting provides improved pathologic complete remission rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Oncol 20:33a, 2002
22. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
23. Pustzai L, Ayers M, Symmans F, et al: Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 22:1, 2003 (abstr 1)